文献速递神经肿瘤

司美替尼治疗复发/进展性儿童低级别胶质瘤的2期PBTC研究:第2、5、6层结果及第1、3、4层长期结局

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.
PubMed 文献 · Neuro Oncol · 2025-01-01

PBTC-029B是一项评估司美替尼治疗复发/进展性儿童低级别胶质瘤的2期试验。第2层14例可评估患者客观缓解率(ORR)为7.1%,第5层23例为21.7%,第6层26例为26.9%;各层2年总生存率均为100%。第1、3、4层5年无进展生存率分别为30.8%、54.2%和51.0%。

要点

  • 司美替尼在多个儿童低级别胶质瘤亚组中提供疾病稳定和缓解。
  • 第2层ORR为7.1%,第5层为21.7%,第6层为26.9%。
  • 部分患者无需额外治疗即获得长期疾病控制。

核心结论

  • 司美替尼在多个儿童低级别胶质瘤亚组中提供疾病稳定和缓解,部分患者无需额外治疗即获得长期疾病控制。

研究设计与样本

  • PBTC-029B是一项2期试验,评估司美替尼在复发/进展性低级别胶质瘤儿童中的疗效。
  • 第2层纳入非NF1相关、BRAF-KIAA1549融合和BRAFV600E突变筛查阴性的复发/进展性毛细胞型星形细胞瘤(PA)。
  • 第5层纳入一种BRAF变异筛查阳性的非PA患者;第6层纳入同意组织筛查但检测失败者。
  • 长期生存分析中,第1层为非NF1相关且一种BRAF变异阳性的PA,第3层为NF1相关pLGG,第4层为非NF1视路/下丘脑肿瘤。

主要发现

  • 第2层14例可评估患者中1例部分缓解(PR)、7例疾病稳定(SD)、6例疾病进展(PD),ORR为7.1%;2年无进展生存率(PFS)/总生存率(OS)分别为57.1%/100%。
  • 第5层23例可评估患者中1例完全缓解(CR)、4例PR、12例SD、6例PD,ORR为21.7%;2年PFS/OS分别为74.8%/100%。
  • 第6层26例可评估患者中7例PR、14例SD、5例PD,ORR为26.9%;2年PFS/OS分别为72.0%/100%。
  • 第1、3、4层无事件患者的中位随访分别为60.4、60.4和58.1个月,5年PFS/OS分别为30.8%/88.9%、54.2%/100%和51.0%/100%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PBTC-029B was a phase 2 trial evaluating efficacy of selumetinib in children with recurrent/progressive low-grade glioma. We report results of strata 2, 5, and 6 with updated survivals for strata 1, 3, and 4. METHODS: Stratum 2 included recurrent/progressive pilocytic astrocytoma (PA) not associated with neurofibromatosis type-1 (NF1) that screened negative for the BRAF-KIAA1549 fusion and BRAFV600E mutation. Stratum 5 enrolled non-PA that screened positive for one of the BRAF aberrations. Stratum 6 enrolled children who consented to tissue screening, but there was an assay failure. For long-term survivals, stratum 1 included non-NF1 PA positive for one of the BRAF aberrations; stratum 3 included NF1-associated pLGG; and stratum 4 included non-NF1 optic pathway/hypothalamic tumors. RESULTS: Stratum 2: among 14 evaluable patients, there was 1 partial response (PR), 7 stable disease (SD), and 6 progressive disease (PD); the overall response rate (ORR) was 7.1%. Two-year progression-free survival (PFS)/overall survival (OS) were 57.1%/100%, respectively. Stratum 5: among 23 evaluable patients, there was 1 complete response (CR), 4 PR, 12 SD, and 6 PD; ORR was 21.7%. Two-year PFS/OS were 74.8%/100%, respectively. Stratum 6: among 26 evaluable patients, there were 7 PR, 14 SD, and 5 PD; ORR was 26.9%. Two-year PFS/OS were 72.0%/100%, respectively. The median follow-up for patients on strata 1, 3, and 4 without events are 60.4, 60.4, and 58.1 months, and 5-year PFS/OS were 30.8%/88.9%, 54.2%/100%, and 51.0%/100%, respectively. CONCLUSIONS: Selumetinib provided stability and responses across many pLGG subgroups, and some patients achieved prolonged disease control without additional therapy.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4. Neuro Oncol. 2025. PMID: 40241281. doi:10.1093/neuonc/noaf065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。